Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 300

1.

Correlation between optical coherence tomographic hyperreflective foci and visual outcomes after intravitreal bevacizumab for macular edema in branch retinal vein occlusion.

Kang JW, Lee H, Chung H, Kim HC.

Graefes Arch Clin Exp Ophthalmol. 2014 Sep;252(9):1413-21. doi: 10.1007/s00417-014-2595-5. Epub 2014 Mar 1.

PMID:
24577742
2.

Spectral-domain optical coherence tomography (SD-OCT) patterns and response to intravitreal bevacizumab therapy in macular edema associated with branch retinal vein occlusion.

Kang HM, Chung EJ, Kim YM, Koh HJ.

Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):501-8. doi: 10.1007/s00417-012-2067-8. Epub 2012 Jun 1.

PMID:
22653439
3.

Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion.

Jaissle GB, Szurman P, Feltgen N, Spitzer B, Pielen A, Rehak M, Spital G, Heimann H, Meyer CH; Retinal Vein Occlusion Study Group.

Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):183-92. doi: 10.1007/s00417-010-1470-2. Epub 2010 Aug 18.

4.

Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion.

Wolf-Schnurrbusch UE, Ghanem R, Rothenbuehler SP, Enzmann V, Framme C, Wolf S.

Invest Ophthalmol Vis Sci. 2011 May 18;52(6):3334-7. doi: 10.1167/iovs.10-6097.

PMID:
21087958
5.

Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion.

Kim M, Yu SY, Kim ES, Bae SH, Park JH, Yu HG, Kwak HW.

Ophthalmologica. 2012;227(3):132-8. doi: 10.1159/000334906. Epub 2011 Dec 29.

PMID:
22212151
6.

Effect of vitreomacular adhesion on antivascular endothelial growth factor therapy for macular edema secondary to branch retinal vein occlusion.

Terao R, Yuda K, Kure K, Inoue T, Ohtsu H, Yanagi Y.

Jpn J Ophthalmol. 2014 Mar;58(2):139-45. doi: 10.1007/s10384-013-0302-4. Epub 2014 Jan 10.

PMID:
24402616
7.

Disrupted foveal photoreceptors after combined cystoid spaces and retinal detachment in branch vein occlusion treated with bevacizumab.

Murakami T, Tsujikawa A, Miyamoto K, Sakamoto A, Ogino K, Muraoka Y, Kurashige Y, Yoshimura N.

Retina. 2012 Oct;32(9):1853-61.

PMID:
22481482
8.

Association between integrity of foveal photoreceptor layer and visual outcome in retinal vein occlusion.

Shin HJ, Chung H, Kim HC.

Acta Ophthalmol. 2011 Feb;89(1):e35-40. doi: 10.1111/j.1755-3768.2010.02063.x. Epub 2010 Dec 14.

9.

Treatment of macular edema due to branch retinal vein occlusion with single or multiple intravitreal injections of bevacizumab.

Yunoki T, Miyakoshi A, Nakamura T, Fujita K, Fuchizawa C, Hayashi A.

Jpn J Ophthalmol. 2012 Mar;56(2):159-64. doi: 10.1007/s10384-011-0114-3. Epub 2012 Jan 14.

PMID:
22246387
10.

Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.

Ehlers JP, Decroos FC, Fekrat S.

Retina. 2011 Oct;31(9):1856-62. doi: 10.1097/IAE.0b013e31820d59a5.

PMID:
21659943
11.

Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.

Ding X, Li J, Hu X, Yu S, Pan J, Tang S.

Retina. 2011 May;31(5):838-45. doi: 10.1097/IAE.0b013e3181f4420d.

PMID:
21293319
12.

Bevacizumab treatment for acute branch retinal vein occlusion accompanied by subretinal hemorrhage.

Zhao L, Li B, Feng K, Han L, Ma Z, Liu Y.

Curr Eye Res. 2015 Jul;40(7):752-6. doi: 10.3109/02713683.2014.952827. Epub 2014 Oct 20.

PMID:
25330134
13.

Intravitreal bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion.

Salinas-Alamán A, Zarranz-Ventura J, Caire González-Jauregui JM, Sádaba-Echarri LM, Barrio-Barrio J, García-Layana A.

Eur J Ophthalmol. 2011 Jul-Aug;21(4):434-9. doi: 10.5301/EJO.2010.6101.

14.

SD-OCT pattern of retinal venous occlusion with cystoid macular edema treated with Ozurdex®.

Coscas G, Coscas F, Zucchiatti I, Glacet-Bernard A, Soubrane G, Souïed E.

Eur J Ophthalmol. 2011 Sep-Oct;21(5):631-6. doi: 10.5301/EJO.2011.7428.

PMID:
21500185
15.

Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.

Puche N, Glacet A, Mimoun G, Zourdani A, Coscas G, Soubrane G.

Acta Ophthalmol. 2012 Jun;90(4):357-61. doi: 10.1111/j.1755-3768.2010.01913.x. Epub 2010 Jun 29.

16.
17.

Ranibizumab for serous macular detachment in branch retinal vein occlusions.

Gallego-Pinazo R, Dolz-Marco R, Pardo-López D, Martínez-Castillo S, Lleó-Pérez A, Arévalo JF, Díaz-Llopis M.

Graefes Arch Clin Exp Ophthalmol. 2013 Jan;251(1):9-14. doi: 10.1007/s00417-012-2023-7. Epub 2012 Apr 25.

PMID:
22527327
18.

Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion.

Donati S, Barosi P, Bianchi M, Al Oum M, Azzolini C.

Eur J Ophthalmol. 2012 Jul-Aug;22(4):607-14. doi: 10.5301/ejo.5000085.

PMID:
22101497
19.

Intravitreal bevacizumab combined with grid photocoagulation in recurrent macular edema secondary to retinal vein occlusion.

Farese E, Cennamo G, Velotti N, Traversi C, Rinaldi M, De Crecchio G.

Eur J Ophthalmol. 2014 Sep-Oct;24(5):761-70. doi: 10.5301/ejo.5000448. Epub 2014 Feb 26.

PMID:
24585424
20.

Visual acuity following intravitreal bevacizumab for macular edema associated with retinal vein occlusion.

Ota M, Tsujikawa A, Miyamoto K, Sakamoto A, Murakami T, Yoshimura N.

Jpn J Ophthalmol. 2010 Nov;54(6):555-64. doi: 10.1007/s10384-010-0878-x. Epub 2010 Dec 30.

PMID:
21191716
Items per page

Supplemental Content

Write to the Help Desk